Dataset from A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008407
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479
prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
coronavirus disease - 2019 (COVID-19). Facility staff and residents in contracted skilled
nursing and assisted living facility networks with a high risk of SARS-CoV-2 exposure will
receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples
will be taken from the nose. Blood samples will be drawn. Participation could last up to 25
weeks and may include up to 19 visits.
创建时间：
2024-11-27
